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The aldose reductase (AR; human AKR1B1/mouse Akr1b3) has been the focus of many
research because of its role in diabetic complications. The starting point of these alter-
ations is the massive entry of glucose in polyol pathway where it is converted into sorbitol
by this enzyme. However, the issue of AR function in non-diabetic condition remains unre-
solved. AR-like enzymes (AKR1B10, Akr1b7, and Akr1b8) are highly related isoforms often
co-expressed with bona fide AR, making functional analysis of one or the other isoform
a challenging task. AKR1B/Akr1b members share at least 65% protein identity and the
general ability to reduce many redundant substrates such as aldehydes provided from lipid
peroxidation, steroids and their by-products, and xenobiotics in vitro. Based on these prop-
erties, AKR1B/Akr1b are generally considered as detoxifying enzymes. Considering that
divergences should be more informative than similarities to help understanding their phys-
iological functions, we chose to review specific hallmarks of each human/mouse isoforms
by focusing on tissue distribution and specific mechanisms of gene regulation. Indeed,
although the AR shows ubiquitous expression, AR-like proteins exhibit tissue-specific pat-
terns of expression. We focused on three organs where certain isoforms are enriched, the
adrenal gland, enterohepatic, and adipose tissues and tried to connect recent enzymatic
and regulation data with endocrine and metabolic functions of these organs.We presented
recent mouse models showing unsuspected physiological functions in the regulation of
glucido-lipidic metabolism and adipose tissue homeostasis. Beyond the widely accepted
idea that AKR1B/Akr1b are detoxification enzymes, these recent reports provide growing
evidences that they are able to modify or generate signal molecules.This conceptually shifts
this class of enzymes from unenviable status of scavenger to upper class of messengers.
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INTRODUCTION
Aldose reductases (AR) are cytosolic monomeric enzymes, belong-
ing to the aldo-keto reductase (AKR) superfamily. This superfam-
ily encompasses more than 150 NAD(P)(H)-dependent oxidore-
ductases distributed in all prokaryotic and eukaryotic kingdoms
including yeast, plant, invertebrates, and vertebrates. They cat-
alyze the reduction of carbonyl groups from a wide variety of
natural or synthetic substrates such as aliphatic and aromatic
aldehydes, ketones, keto prostaglandins, ketosteroids, and xenobi-
otics. Because of overlapping substrates and coenzyme specificities
that could lead to confusion between these closely conserved pro-
teins, a nomenclature system for the AKR superfamily has been
established based on their structural and genetic properties and is
available at www.med.upenn.edu/akr/. Indeed, based on sequence
identity, these proteins are divided in 15 families termed AKR1–
AKR15, each family having less than 40% amino acid sequence
identity with the others. Some families are further subdivided into
subfamilies containing proteins with more than 60% sequence
identity (Jez et al., 1997; Hyndman et al., 2003). To date, the AKR1
family is the major group encompassing 50 variants of the referring
founder protein AKR1A1.
Among the AKR1 family, the AR subgroup (AKR1B) is
one of the most characterized because of its involvement in
human diseases such as diabetic complications resulting from
the ability of AKR1B1 to reduce glucose into sorbitol in a
NADPH+H+dependent manner. In addition to glucose conver-
sion, AKR1B proteins display multiple other activities including
reduction of aldehydes generated by lipid peroxidation, steroids
and their derivatives or by-products, retinoids, xenobiotics, and
prostaglandins.
The AKR1B subfamily contains several proteins with very high
structural similarity to the human former AKR1B1. The AKR1B
proteins share more than 65% sequence identity (Table 1). Accord-
ing to their phylogenetic features and their ability to reduce glu-
cose, they can be classified into two subgroups, i.e., AR (AKR1B1–
6) and aldose reductase-like proteins (ARLP; Akr1b7–16), respec-
tively.
To date, three human AKR1B have been characterized: AKR1B1
(human AR; Bohren et al., 1989), AKR1B10 [also designated as
human small intestine (HSI) reductase; Cao et al., 1998; Hyndman
and Flynn, 1998], and AKR1B15 (Barski et al., 2008; Salabei et al.,
2011), which are encoded by genes tandemly arrayed on chro-
mosome 7q33–35. AKR1B1 seems to be ubiquitously expressed
whereas AKR1B10 expression was only reported in small intes-
tine, colon, liver, and thymus (Cao et al., 1998). A genetic study
recently identified a new gene named AKR1B15 closely related
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Table 1 | Comparison of protein sequence of AKR1B.
% cDNA
identity
% Protein
identity
% C-ter
identity/similarity
Sequences of the 17 C-ter AA
residues
HUMAN
AKR1B1• 100 100 100 100 ALLSCTSHKDYPFHEEF
AKR1B10* 70 71 35 59 NVLQSSHLEDYPFDAEY
AKR1B15 68 68 23 47 DFKEFSHLEDFPFDAEY
MOUSE
Akr1b3• 80 85 70 76 ALMSCAKHKDYPFHAEV
Akr1b7 72 71 52 71 DLLDARTEEDYPFHEEY
Akr1b8* 71 70 23 53 LLPETVNMEEYPYDAEY
Akr1b16 69 70 35 71 GLFAASHNEDFPFHAEY
RAT
Akr1b4• 82 84 70 76 ALMSCAKHKDYPFHAEV
r-Akr1b10 68 69 35 71 GLFAASRNEDFPFHSEY
Akr1b13* 76 71 17 53 LLPETVNMEEFPYDAEY
Akr1b14 69 68 41 65 GLFVTSDEEDFPFHEEY
• or * or , corresponding proteins are encoded by ortholog genes; Bold letter, conserved amino acid residues; AA, amino acid.
to the AKR1B1 and AKR1B10 cluster on chromosome 7, encod-
ing a putative protein sharing 68 and 91% sequence identity with
AKR1B1 and AKR1B10, respectively. AKR1B15 tissue expression
has not been explored so far (Barski et al., 2008; Salabei et al.,
2011).
Four murine Akr1b have been described: Akr1b3 (murine AR;
Gui et al., 1995), Akr1b7 [previously named Mouse vas deferens
protein (MVDP); Pailhoux et al., 1990],Akr1b8 [previously named
fibroblast growth factor-related protein (FR-1); Donohue et al.,
1994], and Akr1b16 (Salabei et al., 2011). Murine AR genes are
located on chromosome 6 (locus 6 B1) and their tandem arrange-
ment suggests (as for the three human AKR1B) that these four
genes arise from an ancestral gene duplication event (Ho et al.,
1999; Ruiz et al., 2011). Like AKR1B1, Akr1b3 and Akr1b16 seem
to be ubiquitously expressed (Joshi et al., 2010; Salabei et al., 2011)
whereas Akr1b7 and Akr1b8 display more restricted tissue distrib-
ution: Akr1b7 is expressed in vas deferens, adrenal glands, gonads,
intestine, white adipose tissue, eye, liver, and kidney (Pailhoux
et al., 1990; Lau et al., 1995; Tirard et al., 2007; Brunskill et al.,
2011; Schmidt et al., 2011). Akr1b8 expression is detected in testis,
heart, adrenal glands, intestine, and liver (Donohue et al., 1994;
Lau et al., 1995; Joshi et al., 2010).
Among rat AR, Akr1b4 seems to be ubiquitously expressed
whereas the other related proteins have a more restricted expres-
sion pattern (MacLeod et al., 2010). Transcripts for Akr1b14 have
been detected in liver, kidney, and adrenals. Those of r-Akr1b10
share this tissue expression pattern but are also found in brain,
heart, and lungs (Endo et al., 2010b). Akr1b13 expression has been
observed at mRNA level in almost all organs, except brain and liver
but the protein remains undetectable in small intestine and colon
(Endo et al., 2011).
Several studies allowed identification of Akr1b4, Akr1b13, and
Akr1b14 as the orthologs of mouse Akr1b3, Akr1b8, and Akr1b7,
respectively (Barski et al., 2008; Endo et al., 2011). This phyloge-
netic analysis between rat and mouse AR has some limits: Akr1b14
and Akr1b7 do not exactly display the same expression pattern.
Indeed, vas deferens is the major site of Akr1b7 expression whereas
Akr1b14 is barely detectable in this tissue. Despite high sequence
identity, the two promoters differ by a short 77-bp region absent
in rat sequence which confers vas deferens targeted expression and
androgen responsiveness to the Akr1b7 gene (Val et al., 2002).
Identification of the mechanisms regulating expression of
AKR1B/Akr1b is a necessary step to understand their physi-
ological functions. Nevertheless, the precise identification and
determination of spatial distribution of AKR1B/Akr1b in healthy
tissues remains a difficult task, as it requires powerful and
specific immunological or nucleic probes to allow discrimina-
tion between these closely related isoforms. For that reason,
we designed immunological probes targeting the most divergent
domain among these enzymes that encompass the 17 C-terminal
amino acid residues (Table 1). Indeed,using this C-terminal region
critical to substrate specificity (Bohren et al., 1992), we developed
immunological tools discriminating Akr1b7, Akr1b3, and Akr1b8
isoforms (Lefrançois-Martinez et al., 2004). Similarly, the most
discriminating nucleotide probes or primers should be carefully
designed from 5′- to 3′-untranslated regions while open read-
ing frame should be avoided whenever possible. Knowing that in
mammals, AR genes (i.e., human AKR1B1 gene, murine Akr1b3,
and rat Akr1b4) display a broad tissue expression pattern, it can
be assumed that in normal conditions, most of their activities
are involved in maintaining general cellular homeostasis through
osmotic regulation or detoxification processes.
This review will focus on the most characterized AKR1B pro-
teins: AKR1B1, Akr1b3, Akr1b7, Akr1b8, and AKR1B10. To date
many in vitro and ex vivo studies have examined and carefully
described their enzymatic activities and defined their substrate
specificities. These studies have enlightened some redundancy
in substrate specificities that can be confusing when considering
that various isoforms may coexist in the same tissue. In light of
these enzymatic data, one of the most challenging issue regarding
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AKR1B enzymes would now be to explore their distinct biological
functions in specific physiological or pathological processes. The
focus of this review is to integrate most recent data on specific
regulations of AR genes with enzymatic and functional data, in
selected organs involved in endocrine and metabolic function, i.e.,
the adrenal gland, enterohepatic tissue, and white adipose tissue.
AKR1B AND ADRENAL ENDOCRINE FUNCTION
The adrenal gland has two anatomically and functionally different
components: the outer cortex which provides mineralocorticoids
from the zona glomerulosa, glucocorticoids from the zona fascic-
ulate, and the inner medulla in which chromaffin cells produce
adrenal catecholamines, i.e., epinephrine and norepinephrine and
various neuropeptides.
Acute and chronic adrenal cortex steroidogenesis is regu-
lated mainly through activation of the cAMP-dependent pro-
tein kinase (PKA) signaling pathway mediated by the pituitary
adrenocorticotropin hormone (ACTH).
Excess levels of glucocorticoid in the plasma in turn induce
a negative feedback on ACTH production resulting in blunted
ACTH-dependent steroidogenesis in the adrenal gland. This
blockade of the hypothalamic-pituitary-adrenal axis can be exper-
imentally recapitulated by dexamethasone treatment (a syn-
thetic glucocorticoid). In adrenals, cAMP-induced PKA activation
results at least in the phosphorylation of transcription factors
such as steroidogenic factor 1 (SF-1), CCAAT Enhancer Binding
Protein (C/EBP), and cAMP response element-binding protein.
These, in turn stimulate transcription of genes encoding steroido-
genic enzymes and proteins responsible for cholesterol metab-
olism, mobilization and transport. Therefore, adrenal steroido-
genesis is strongly associated with production of endogenous
harmful lipid aldehyde by-products including isocaproaldehyde
(4-methylpentanal) derived from cholesterol side chain cleavage
(the first step of steroid synthesis) and 4-hydroxynonenal (4-
HNE). Interestingly, previous studies have established that the
adrenal gland is one of the major sites for human and murine
AR expression (Lau et al., 1995; Hyndman and Flynn, 1998).
Akr1b8/AKR1B10: EXPRESSION PROFILE, DETOXIFICATION FUNCTION
(TABLES 2 AND 3)
Akr1b8 messenger was observed by in situ hybridization analysis
in fetal and adult murine adrenal cortex and remained undetected
in the medulla (Lau et al., 1995). Nevertheless, dexamethasone-
induced ACTH suppression had no effect on Akr1b8 protein
levels (Lambert-Langlais et al., 2009) suggesting that its biolog-
ical function would not be associated to the ACTH-dependent
steroidogenic activity. Indeed, isocaproaldehyde reductase activity
was abolished in adrenocortical Y1 cells lacking Akr1b7 (due to
stable antisense expression) in the presence of unaltered Akr1b8
protein levels (Lefrancois-Martinez et al., 1999). Accordingly,
isocaproaldehyde accumulated and resulted in cellular toxicity
despite the presence of Akr1b8. On the basis of these functional
studies, of its enzymatic constants and constitutive expression,
Akr1b8 does not appear to be the major isocaproaldehyde reduc-
tase in the adrenal cortex (Martinez et al., 2001). Although all
murine AR exhibit 4-HNE reductase activity, Akr1b8 seems to
be the most efficient HNE reductase in mouse tissues (Srivastava
et al., 1998; Martinez et al., 2001). This suggests that adrenocor-
tical expression of Akr1b8 could be dedicated to detoxification
of aldehyde lipids that are present in large amounts in the cortex
(Burczynski et al., 1999). Nevertheless, functional demonstration
remains to be established.
AKR1B10 mRNA has been detected in adrenal glands using a
human RNA Master Blot, but to date, there is no information avail-
able on its in situ localization and transcriptional control in this
organ (Hyndman and Flynn, 1998). Although both AKR1B1 and
AKR1B10 human AR display 4-HNE reductase activity, AKR1B10
exhibits a higher activity and product turn over than AKR1B1
(Shen et al., 2011). Both AKR1B1 and AKR1B10 isoforms are
expressed in the human adrenal gland and ex vivo studies revealed
that they also share the ability to reduce isocaproaldehyde (Hynd-
man and Flynn, 1998). Nevertheless, in a comparative enzymatic
study, Hara and colleagues showed that AKR1B1 had a more effec-
tive isocaproaldehyde reductase activity than AKR1B10, suggesting
that the latter was unlikely to play a major role in the detoxification
of steroidogenic by-products (Endo et al., 2009b).
Since its identification in human hepatocellular carcinoma,
AKR1B10 was shown to be differentially expressed in other tumor
and normal tissues (Cao et al., 1998; Fukumoto et al., 2005; Yoshi-
take et al., 2007; Rajkumar et al., 2010). AKR1B10 was suggested to
be a biomarker of smoker’s non-small cell lung carcinomas (Fuku-
moto et al., 2005) and to be involved in drug resistance (Matsunaga
et al., 2012).
Human adrenocortical carcinoma (ACC) are rare malignant
tumors generally associated with a poor prognosis (Libè et al.,
2007). In order to identify molecular predictors of malignancy
and of survival, 153 unilateral adrenocortical tumors were stud-
ied by microarray (http://www.ebi.ac.uk/arrayexpress, experiment
E-TABM-311). Unsupervised clustering analysis was performed
which allowed robust discrimination of malignant and benign
tumors. On the basis of this analysis, AKR1B10 was not found to
be associated with the ACC group (de Reyniès et al., 2009).
Akr1b7: EXPRESSION PROFILE, DETOXIFICATION FUNCTION, AND
PARACRINE ACTION (TABLES 2 AND 3)
High levels of Akr1b7 transcripts were initially observed by in situ
hybridization in fetal and adult murine adrenal cortex but were
undetectable in the medulla (Lau et al., 1995). We confirmed these
results by immunohistochemistry experiments which allowed
us to further restrict Akr1b7 expression to the zona fasciculata
(Aigueperse et al., 1999). In vivo, ACTH suppression with dex-
amethasone treatment resulted in a marked decrease of Akr1b7
mRNA levels that were restored when the treated mice were
injected with exogenous ACTH. This ACTH or cAMP-induced
Akr1b7 transcription was blocked by a PKA inhibitor (H89) in
the murine adrenocortical ATC and Y1 cell lines, respectively
(Aigueperse et al., 1999; Ragazzon et al., 2006).
Adrenal expression and ACTH regulation of Akr1b7 are sup-
ported by three SF-1 binding sites and other cis-elements located
in the 5′-flanking regulatory region of the gene. Using trans-
genic mice and cell transfection experiments, we delimited a
cryptic SF-1 response element (SFRE) 102 bp upstream of the
transcription start site. This SFRE supported basal adrenal pro-
moter activity. Two other SFREs were identified further upstream.
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Table 2 | Localization and regulation of AKR1B expression in adrenal gland.
Isoforms Localization Analyses Control by ACTH/
cAMP
Transcriptional
regulators
Reference
HUMAN
AKR1B1 Cortex IHC, RNA Master blot + n.d. a,b
AKR1B10 Adrenal RNA master blot n.d. n.d. b
AKR1B15 n.d. n.d. n.d. n.d. –
MOUSE
Akr1b3 Cortex+medulla WB No No a,c
Akr1b7 Cortex NB, WB, IHC, ISH + Sp1, C/EBPβ, SF-1 a,c,d,e,f,g
Akr1b8 Cortex WB, ISH No No a,c,d
Akr1b16 n.d. n.d. n.d. n.d. –
RAT
Akr1b4 Cortex RT-PCR, IHC, WB n.d. n.d. h,i
Akr1b13 Adrenal RT-PCR n.d. n.d. h
Akr1b14 Cortex ISH, WB + n.d. j
, Intra-adrenal tissular localization was not specified; n.d., not determined; NB, Northern blot; WB, Western blot; RT-PCR, reverse transcription-polymerase chain
reaction; ISH, in situ hybridization; IHC, immunohistochemistry.
aLambert-Langlais et al. (2009), bHyndman and Flynn (1998), cMartinez et al. (2001), dLau et al. (1995), eAigueperse et al. (1999), fVal et al. (2004), gAigueperse et al.
(2001), hEndo et al. (2009a), iMacLeod et al. (2010).
Table 3 | Kinetic constants of AKR1B toward 4-hydroxynonenal, isocaproaldehyde, and prostaglandin H2.
Substrates 4-Hydroxynonenal Isocaproaldehyde Prostaglandin H2e
Km (µM) K cat (s−1) Km (µM) K cat (s−1) Km (µM) Vmax
(nmol/min/mg)
HUMAN
AKR1B1 716a 0.84a 1b 0.66b 1.9 44
AKR1B10 31a 2.01a 330c 0.72c No activity
AKR1B15 n.d. n.d. n.d. n.d. n.d.
MOUSE
Akr1b3 665a 0.82a 62d 1.3d 9.3 26
Akr1b7 256a 0.1a 320d 0.38d 3.8 53.4
Akr1b8 230a 3.18a 71d 0.03d No activity
Akr1b16 n.d. n.d. n.d. n.d. n.d.
RAT
Akr1b4 33f 0.23f n.d. n.d. n.d.
r-Akr1b10 1.6g 0.05g 11g 0.03g n.d.
Akr1b13 30f 0.18f n.d. n.d. n.d.
Akr1b14 7.6h 0.02h 16h 0.03h n.d.
n.d., not determined.
References (for comparison data were converted in µM for the Km and in s−1 for the Kcat): aJoshi et al. (2010), bMatsuura et al. (1996), cMartin and Maser (2009),
dMartinez et al. (2001), eKabututu et al. (2009), fEndo et al. (2009a), gEndo et al. (2010b), hEndo et al. (2010a).
The site at −458 was a bona fide SFRE playing an essential
role for both basal promoter activity and cAMP responsiveness
whereas the site at −503 conferred intrinsic cAMP-sensing abil-
ity (Martinez et al., 2003; Val et al., 2004). Two other binding
sites for the trans-acting factors Sp1 and C/EBPβ at position
−52 and −61, respectively, also contributed to the transcrip-
tional cAMP responsiveness (Aigueperse et al., 2001; Table 2 and
Figure 1).
Aldose reductases are able to reduce isocaproaldehyde that is
produced in large amount in the adrenal cortex during steroido-
genesis. Indeed, the first step of steroidogenesis is the removal of
the cholesterol side chain by the P450scc enzyme, resulting in the
formation of pregnenolone and isocaproaldehyde. Furthermore,
isocaproaldehyde is a cytotoxic aldehyde whose accumulation in
Y1 cells decreased their viability (Lefrancois-Martinez et al., 1999).
In vitro studies revealed that Akr1b3, Akr1b7, and Akr1b8 all had
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FIGURE 1 | Schematic representation of theAkr1b7 promoter. The DNA binding site for transcription factors and nuclear receptors required for the Akr1b7
specific expression in adrenal gland (pink boxes) and in enterohepatic tissue (green boxes) are shown. LXR binding sites are involved in both adrenal and
intestine Akr1b7 expression.
the ability to reduce isocaproaldehyde. Their kinetic constants sug-
gested that isocaproaldehyde was a major substrate for Akr1b3
and Akr1b7, and a poor substrate for Akr1b8 (Martinez et al.,
2001; Table 3). Akr1b7 silencing in Y1 adrenocortical cells dis-
rupted cAMP-induced isocaproaldehyde reductase activity. This
strongly suggested that Akr1b7, rather than Akr1b3, was the
main isocaproaldehyde reductase in the adrenal gland (Lefrancois-
Martinez et al., 1999). These observations further indicate that
ACTH not only coordinates expression of enzymes responsible for
the biosynthesis of steroids, but also of non-steroidogenic enzymes
involved in the detoxification of reactive aldehydes generated
during steroidogenesis.
In a previous study, Madore and colleagues proposed that
AKR1B5, initially characterized as the bovine 20α-hydroxysteroid
dehydrogenase, ensured prostaglandin F2α synthase (PGFS) activ-
ity in the endometrium (Madore et al., 2003). Thereafter, we
have established by in vitro studies, that this property could be
extended to other but not all AKR1B enzymes. Indeed, AKR1B1,
Akr1b3, and Akr1b7 were shown to catalyze the reduction of
prostaglandin H2 (PGH2) into PGF2α (Table 3). In contrast,
Akr1b8 and AKR1B10 recombinant proteins were devoid of this
PGH2 9-,11-endoperoxide reductase activity. This activity has
not been investigated for Akr1b16, AKR1B15, and rat AR so
far. Importantly, based on their kinetic parameters, recombinant
AKR1B1,Akr1b3, and Akr1b7 displayed better PGF synthase activ-
ities than the previously characterized PGF synthases in mammals
(Kabututu et al., 2009).
Prostaglandins are paracrine/autocrine cell mediators sharing a
common precursor, PGH2, which is synthesized from free arachi-
donic acid by the cyclooxygenases type 1 (COX-1) or type 2
(COX-2). COX-1 is regarded as a constitutively expressed enzyme.
COX-2, on the other hand, is undetectable in most tissues in basal
conditions but can be induced by various mitogenic agents and
inflammatory stimuli (Ramsay et al., 2003). Following these obser-
vations, we carefully examined the PGF2α biosynthetic pathway in
the adrenal gland (Lambert-Langlais et al., 2009).
PGF2α was secreted by both cortical (steroidogenic cells) and
medullary (chromaffin cells) compartments of the adrenal gland.
In primary adrenocortical cell culture, PGF2α release was induced
2.5-fold by ACTH exposure which was correlated with ACTH-
responsiveness of both COX-2 and Akr1b7. Using over- and down-
expression strategies in cell lines, we demonstrated the pivotal
role of Akr1b7 in ACTH-induced PGF2α release and its functional
coupling with COX-2. In the adrenal medulla, PGF2α production
seemed to be resulting from the coordinated activities of Akr1b3
and COX-1. In the adrenal, expression of the PGF2α specific recep-
tor (FP) was restricted to chromaffin cells, suggesting that both
autocrine (within the medulla) and paracrine (between steroido-
genic and chromaffin cells) mechanisms were relaying PGF2α
action. Indeed in the chromaffin cell line MPC862L, PGF2α was
able to repress both basal and glucocorticoid-induced dopamine
release. By comparing PGF2α-responsiveness of isolated cells and
whole adrenal cultures, we demonstrated that PGF2α repressed
glucocorticoid secretion by an indirect mechanism involving a
decrease in catecholamine release, which in turn decreased adrenal
steroidogenesis.
These results allowed us to propose a new mechanism for an
intra-adrenal feedback loop, in which AR play a pivotal role in
the regulation of adrenal endocrine functions (Figure 2). The
mechanism that we proposed was the following: (1) In basal con-
ditions, PGF2α is constitutively secreted by chromaffin cells (by the
coupling of COX-1 and Akr1b3), thus regulating catecholamines
production and also limiting their paracrine action on steroido-
genesis. (2) During a stress situation, ACTH transiently induces
COX-2 and Akr1b7 expression, which results in PGF2α production
inside the cortex. PGF2α produced in the cortex then represses cat-
echolamines release by the medulla, via a paracrine action on its
FP receptor. Decreased catecholamines release in turn reduces the
effect of ACTH on glucocorticoids production (Lambert-Langlais
et al., 2009).
Akr1b3/AKR1B1 EXPRESSION PROFILE, DETOXIFICATION FUNCTION,
AND PARACRINE ACTION
By using different adrenal cell lines, we managed to detect Ak1b3
protein in the adrenocortical Y1 cells, and in the chromaffin
MPC862L cells. These results confirmed that, unlike other murine
AR, Akr1b3 is constitutively expressed in the whole adrenal gland
(Lambert-Langlais et al., 2009). In Y1 adrenocortical cell line
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FIGURE 2 | Proposed model integrating dual functions of aldose
reductases in the regulation of adrenal endocrine functions. Free
arachidonic acid (AA) is metabolized into PGH2 by COX enzymes and then
converted into PGF2α by PGFS of the AKR1B family. FP receptor expression
is restricted to the medullary zone. PGF2α synthesized in both the cortex
and medulla thus signals in an autocrine/paracrine manner on chromaffin
cells. This inhibits catecholamines production. Catecholamines produced in
the medulla normally stimulate glucocorticoids release by the cortex.
Decreased catecholamines production in response to PGF2α stimulation
thus results in a decrease in glucocorticoids production. The differential
expression and regulation of both COX and AKR1B enzymes within the
adrenal zones could allow the adjustment of PGF2α production to limit
stress response or control basal steroidogenesis by finely tuning
glucocorticoids secretion. In basal conditions, chromaffin cells of the
medullary zone constitutively secrete PGF2α, through the functional
coupling between COX-1 and possibly the PGFS Akr1b3. Under stress
conditions, the resulting ACTH surge induces COX-2 expression and
sustains Akr1b7 levels in the cortex. The functional coupling between
COX-2 and Akr1b7 triggers a PGF2α surge that could act as a local paracrine
feedback to limit catecholamine-mediated glucocorticoid release. After the
stress response has ended, COX-2 returns to undetectable levels. The
coupling between Akr1b7 and COX-2 does not take place. Akr1b7 then
functions only as a detoxifying enzyme of the harmful aldehydes produced
under chronic/basal stimulation of steroidogenesis. Catecho,
catecholamines; Gluco, glucocorticoids.
and during in vivo hormonal manipulations, cAMP appeared to
have no significant effect on Akr1b3 expression suggesting that
its expression was insensitive to ACTH (Martinez et al., 2001;
Table 2).
Akr1b3 is also involved in the detoxification of toxic carbonyls.
Even if Akr1b7 is the main isocaproaldehyde reductase and Akr1b8
the principal 4-HNE reductase, Akr1b3 is also able to reduce these
toxic compounds. This suggests that Akr1b3 can take part in the
elimination of these compounds in basal physiological conditions
(Lefrancois-Martinez et al., 1999; Martinez et al., 2001). More-
over, Akr1b3 is constitutively expressed in cortical and medullary
cells, where it could be coupled to COX-1 to synthesize PGF2α (see
above paragraph).
Despite its expected participation in the elimination of toxic
compounds and in the production of signal molecules (PGF2α),
there is no report of adrenal dysfunction in mice lacking Akr1b3
(Akr1b3−/−; Aida et al., 2000; Ho et al., 2000). This absence
of adrenal phenotype may result from functional redundancy
between the different family members present in the gland
(Akr1b7 and Akr1b8).
AKR1B1 expression has initially been detected using a RNA
master blot in human adrenal gland (Hyndman and Flynn, 1998).
More recently, immunohistochemistry experiments allowed us
to assign AKR1B1 to the cortical compartment of the gland
(Lambert-Langlais et al., 2009). In NC1-H295, a human adreno-
cortical tumor cell line, AKR1B1 mRNA levels were induced
by forskolin (adenylyl cyclase inducer) treatment (Lefrançois-
Martinez et al., 2004). This suggested that similarly to Akr1b7,
AKR1B1 gene expression could be sensitive to ACTH control.
However, the molecular mechanisms and cis-acting elements
ensuring ACTH/cAMP responsiveness of AKR1B1 gene have
remained unexplored.
For years, AKR1B1 had been considered as the major iso-
caproaldehyde reductase in the adrenal gland (Matsuura et al.,
1996). The NADPH-dependent isocaproaldehyde reductase activ-
ity harbored by AKR1B1 was inhibited by tolrestat while the
murine isocaproaldehyde reductase Akr1b7 was insensitive to
this pharmacological inhibitor (Matsuura et al., 1996; Lefrancois-
Martinez et al., 1999). We demonstrated that AKR1B1 was also
endowed with 9-,11-endoperoxide reductase activity (Kabututu
et al., 2009). The conversion of PGH2 into PGF2α, catalyzed by
AKR1B1, strictly dependent on the presence of NADPH, was
inhibited by tolrestat whereas Akr1b7 PGFS activity was insensitive
to AR inhibitors.
We showed that in the normal human adrenal gland, AKR1B1
and COX-2 were co-localized in steroidogenic cortical cells
(Lambert-Langlais et al., 2009). Therefore, the human adrenal cor-
tex could also have the potential to produce PGF2α in response
to ACTH. With respect to their hormonal regulation in the
adrenal cortex and their reductase activity toward common sub-
strates, we have postulated that AKR1B1 could be considered as
a functional ortholog of Akr1b7 in the human adrenal cortex
(Lefrançois-Martinez et al., 2004). The possibility that the PGFS
activity of AKR1B1 could be involved in an intra-adrenal feed-
back loop between endocrine activities of cortical and medullary
compartments in human adrenal gland remains to be explored.
Given the high expression of AKR1B1 in the adrenal cortex we
evaluated alterations in its expression in association with human
adrenal disorders. The relative abundance of AKR1B1 mRNA was
decreased in ACCs when compared to benign tumors, Cushing’s
hyperplasia, or normal adrenals (Lefrançois-Martinez et al., 2004).
These data provided evidence that expression of AKR1B1 was
decreased in adrenocortical cancer. This was further confirmed by
the unsupervised clustering analysis of the human adrenal tumors
transcriptome performed by de Reyniès et al. (2009), indicating
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that decreased expression of AKR1B1 correlated with malignancy
for the molecular diagnosis of adrenal tumors.
AKR1B AND GLUCIDO-LIPIDIC HOMEOSTASIS
AKR1B IN ENTEROHEPATIC TISSUES
Excessive nutrient intake is detrimental for cells and tissues. In
mammals, the liver converts excess dietary carbohydrates into
triglycerides through de novo lipogenesis. Two transcription fac-
tors, carbohydrate-responsive element-binding protein (ChREBP)
and sterol responsive element-binding protein-1c (SREBP-1c)
emerged as major mediators of glucose and insulin action in the
control of both glycolysis and lipogenesis in the liver. The liver X
receptors (LXR) are oxysterol activated transcription factors act-
ing as important metabolic regulators of the lipogenic pathway.
Indeed, LXRs ensure the transcriptional control of SREBP-1c in
response to insulin and of ChREBP. Moreover, direct targets of
LXRs include other lipogenic genes such as fatty acid synthase
(Fas) and stearoyl-CoA desaturase 1 (SCD1; Chen et al., 2004; Pos-
tic and Girard, 2008; Kim et al., 2009). The farnesoid X receptor
(FXR)/bile acid receptor is another nuclear receptor that plays
an important role in maintaining bile acid, lipid, and glucose
homeostasis since its activation has been shown to lower blood
triglyceride and cholesterol levels and to improve insulin sen-
sitivity in diabetic mouse models (Zhang and Edwards, 2008).
In enterocytes, FXR was shown to protect against the cytotoxic
effects of bile acids by increasing expression of binding proteins
and transporters (Schmidt and Mangelsdorf, 2008).
Akr1b8/AKR1B10: from cell detoxification to lipid synthesis
Previous analyses performed by RNAse protection assays reported
very weak levels of Akr1b8 transcript (Lau et al., 1995) in the
mouse intestine and absence of expression in the adult liver.
These observations were partially revised by Joshi et al. (2010)
who showed high Akr1b8 expression all along the adult intestinal
tract and moderate expression in the liver. Akr1b8 expression was
initially described to be up-regulated during the early phase of
the cell cycle and induced by growth promoting agents [fibrob-
last growth factor (FGF) and epidermal growth factor (EGF)],
as well as by hypertonic stress (Donohue et al., 1994; Hsu et al.,
1997). Although Akr1b8 displayed a strong expression in mouse
colon cancer cells (Joshi et al., 2010) and was suggested to be a
target gene for NF-E2 related factor 2 (Nrf2) transcription fac-
tor that controls intestinal detoxification response (Varady et al.,
2011), its expression and regulation in healthy liver and intestine
remained elusive. A recent study investigating bile acids impacts
on Akr1b7 expression showed that enterohepatic expression of
Akr1b8 was insensitive to bile acids (Schmidt et al., 2011). Akr1b8
enzymatic activities were extensively studied regarding its ability
to reduce the highly reactive 4-HNE produced during peroxida-
tion of polyunsaturated fatty acids (Srivastava et al., 1998). In vitro
enzymatic studies reported that multiple members of the AKR1B
group, including Akr1b8, were endowed with the ability to reduce
phospholipid aldehydes derived from lipid peroxidation. Com-
pared with AKR1B1 or Akr1b7, Akr1b8 activity was more efficient
with the reduction of short chain aldehydes such as 1-palmitoyl-
2-arachidonoyl-sn-glycero-3-phosphocholine and 1-pamitoyl-2-
arachidonoyl-sn-glycero-3-phosphoglycerol (Spite et al., 2007). In
line with the high lipid metabolic activities in Akr1b8 produc-
ing sites, it was proposed that Akr1b8 was acting physiologically
as a scavenger of toxic aldehydes derived from peroxidation of
endogenous or dietary lipids.
Beside its aldehyde reductase activity, Akr1b8 was shown to
associate with the lipogenic acetyl-CoA carboxylase α (ACCA) in
murine colon cancer cells (Joshi et al., 2010). ACCA is a rate-
limiting enzyme of de novo synthesis of fatty acids, catalyzing
the formation of malonyl-coA by ATP-dependent carboxylation
of acetyl-coA. This interaction protects ACCA from proteasomal
degradation and consequently allows increased fatty acid synthesis
that leads to production of lipid second messengers that promote
cell proliferation (Chajès et al., 2006). Whether Akr1b8 is also
involved in the stability of ACCA in healthy enterocytes has not yet
been determined. In order to associate gene signature with meta-
bolic network, a genetic study integrating quantitative trait locus
(QTL) mapping and network modeling led to knock-out (KO) the
three corresponding identified genes, among which Akr1b8 (Derry
et al., 2010). Akr1b8−/−mice phenotype was very briefly described
in this study suggesting a more specific perturbation in fat tissue
homeostasis rather than in the liver or intestine (see below).
The AKR1B10 gene has recently been determined as the human
ortholog of Akr1b8 (Joshi et al., 2010). Its expression was pri-
marily detected in healthy colon, small intestine, and liver (Cao
et al., 1998) and was found up-regulated with their correspond-
ing tumorigenic transformation (Cao et al., 1998; Yan et al., 2007;
Heringlake et al., 2010; Liu et al., 2012). This was also observed in
lung and breast cancers suggesting that AKR1B10 overexpression
could be associated with a broader tumor phenotype. In human
hepatocarcinoma, insulin or EGF enhanced AKR1B10 expression
through the activator protein-1 (AP1) mitogenic signaling. This
enhanced tumor development and progression through elimina-
tion of cytotoxic carbonyls and promotion of lipogenesis (Liu et al.,
2012). The treatment of human colon cancer SW-480 and HT-
29 cell lines with proteasome inhibitors known to increase the
expression of Nrf2-regulated genes induced AKR1B10 expression
suggesting that AKR1B10 could be a target of the Nrf2 transcrip-
tion factor (Ebert et al., 2011). Nrf2 responsiveness of AKR1B10
gene was further demonstrated by co-transfection experiments of
AKR1B10 promoter luciferase reporter constructs in human lung
adenocarcinoma cell lines (Nishinaka et al., 2011; Figure 3).
AKR1B10 was the first AKR1B protein which was demonstrated
to enhance cell proliferation and promote cell survival through its
ability to interact with and stabilize ACCA in breast cancer cells
(Ma et al., 2008) and in colon cancer cells (Wang et al., 2009).
AKR1B10 mediates ACCA stability through physical association.
This was shown to affect fatty acid/lipid synthesis, mitochondrial
function, and oxidative status. Identification of Akr1b8/AKR1B10
protein domain interacting with ACCA would be helpful to pre-
dict this characteristic for other AKR1B proteins and to develop
targeted therapeutic strategies for the modulation of de novo fatty
acid synthesis in cancer cells.
We are exposed daily to α,β-unsaturated aldehyde and trans-
2-hexenal through food and drink consumption (Stout et al.,
2008). This persistent exposure to electrophilic carbonyls requires
an effective defense system to protect intestinal cells from irre-
versible damage. Similarly to Akr1b8, in vitro enzymatic studies on
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FIGURE 3 | Schematic representation of theAKR1B1,Akr1b3, and
AKR1B10 promoters. Cis- and trans-acting factors shown to be involved in
stress responsiveness are indicated. TonE, tonicity response element; AP1,
activator protein-1 binding site; ARE, antioxidant response element; C/EBP,
CCAAT enhancer binding protein binding site; Sp1, selective promoter factor
1 binding site.
AKR1B10 demonstrated a highly specific ability to reduce phys-
iological levels of 4-HNE and other alpha and beta-unsaturated
carbonyls in both their free or glutathione-conjugated form
(Martin and Maser, 2009; Zhong et al., 2009). Expression of
AKR1B10 may reflect the requirement for intestinal cells to
protect against the dietary, lumen microbial and lipid-derived
carbonyls.
Although physiological integration of all these data remains
difficult, this suggests that the beneficial role of Akr1b8/AKR1B10
in the protection of healthy cells against lipid peroxidation could
switch, in the case of cancer, into a deleterious role promoting cell
proliferation through stabilization of ACCA (Figure 4).
Akr1b7: improving (liver) metabolic capacity
A target for metabolic nuclear receptors (Figure 1 and Table 4).
Several studies reported specific Akr1b7 expression in the small
intestine (Volle et al., 2004; Ge et al., 2011; Schmidt et al., 2011)
within the epithelial cells of the villi (Lau et al., 1995) with a
decreasing gradient from the duodenum to the ileum. This expres-
sion has been shown to be under the control of oxysterol activated
LXR/retinoic X receptor (RXR) heterodimers acting through three
LXR response elements (LXRE) located in the Akr1b7 proximal
promoter (LXRE3:−259 to−244, LXRE1:−236 to−221, LXRE2:
−153 to −168 from the transcription start site). Two of these
cis-acting elements were specific for regulation by the alpha LXR
isoform (Volle et al., 2004).
Two other recent reports showed that Akr1b7 gene transcrip-
tion in the small intestine, colon and liver was also controlled by
bile acids through a FXR response elements (FXRE) located at
position−292 to−280 on the promoter (Ge et al., 2011; Schmidt
et al., 2011).
Several nuclear receptors, including FXR, pregnane X recep-
tor (PXR) and constitutive androstane receptor (CAR), have
been shown to protect against the cytotoxic effects of bile acids
by increasing expression of binding proteins, transporters, and
enzymes that detoxify bile acids (Zollner et al., 2006; Schmidt and
Mangelsdorf, 2008). The combined use of KO mouse models for
PXR/CAR receptors and pharmacological activators allowed iden-
tification of Akr1b7 as one of their target genes in the liver (Liu
et al., 2009; Table 4 and Figure 1).
Although molecular mechanisms mediating metabolic regula-
tion of Akr1b7 expression in the liver and intestine were profusely
examined using genetic models or forced expression systems, there
is no direct evidence for Akr1b7 expression in liver sections or in
isolated hepatocytes, to date.
Detoxifying lipid aldehydes. Wild-type mice treated with
PCN (pregnenolone-16α-carbonitrile; a PXR agonist) exhibited
a decrease in malondialdehyde (MDA) levels (another by-product
of polyunsaturated fatty acid peroxidation) compared with their
vehicle-treated counterparts. The effect of PCN on MDA was abol-
ished in Pxr−/− mice. The authors suggested that PXR played a
role in alleviating lipid peroxidation in small intestine. Since the
induction of Akr1b7 expression by PCN was also abolished by PXR
KO, the effects of PXR on lipid peroxidation could be mediated, at
least in part, by modulation of Akr1b7 expression (Liu et al., 2009;
Ge et al., 2011; Schmidt et al., 2011).
In light of the ability of Akr1b7 to reduce 4-HNE, Volle et al.
have compared the status of lipid peroxidation in the small intes-
tine of wild-type and Lxrα−/− mice by measuring MDA levels. In
the duodenum, a significant decrease in MDA concentrations was
seen when wild-type mice were treated with T091317 (a synthetic
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FIGURE 4 | Role of AKR1B10 and Akr1b8 in the regulation of lipid
synthesis and contribution in promoting cancer. In human cancer cells,
ACCA is protected against ubiquitination-proteasome dependent
degradation through its association with AKR1B10. Stabilization of ACCA
increases fatty acids synthesis. This protects cell from apoptosis by
preventing depletion of phospholipids, mitochondrial membrane lesions,
and oxidative stress. The dual capacity of AKR1B10 to stimulate
lipogenesis and to detoxify carbonyls and drugs thus contributes to
enhance cell proliferation/survival. In murine cancer cells, Akr1b8 was also
shown to stabilize ACCA thereby modulating fatty acid synthesis. The
impact of Akr1b8-mediated ACCA stabilization on mitochondrial function
and oxidative stress is still unknown.
agonist of LXR). This effect was not observed in Lxrα−/− mice,
where T091317 was unable to induce Akr1b7. The authors sug-
gested that increased levels of LXRα in the small intestine and
its activation by oxysterols could in turn, up-regulate the expres-
sion of detoxifying genes which could ultimately reduce oxidative
stress (Volle et al., 2004). However, although the decrease in MDA
contents is clearly a LXR dependent mechanism, the direct involve-
ment of Akr1b7 seems unlikely. Indeed overexpression of Akr1b7
in vivo does not alter MDA levels (Ge et al., 2011).
Detoxifying bile acids or lipid peroxidation induced by bile acids
excess (Figure 5). Recently three independent studies proposed
that Akr1b7 or its rat ortholog Akr1b14 could be involved in bile
acid metabolism and/or signaling (Endo et al., 2011; Ge et al., 2011;
Schmidt et al., 2011).
Bile acids are cholesterol-derived molecules produced for its
solubilization in the gallbladder and intestine by forming mixed
micelles with cholesterol and phospholipids. They are required for
the activation of some pancreatic enzymes and for the absorption
of cholesterol, lipid soluble vitamins and to a lesser extent, triglyc-
erides and fatty acids from the intestine (Hylemon et al., 2009).
They also act as signaling molecules by acting as ligands for several
nuclear receptors including FXR and PXR or the membrane Gαs
protein-coupled receptors TGR5 as well as Gαi protein-coupled
receptors. Hence, bile acids contribute to the regulation of their
own synthesis, fatty acid, lipid, and lipoprotein synthesis as well as
glucose metabolism in the liver.
An in vitro enzymatic study using recombinant Akr1b14
(rat) and Akr1b7 (mouse) proteins showed that conjugated and
unconjugated bile acids (chenodeoxycholic acid (CDCA)/glyco-
CDCA and hyodeoxycolic acid (HDCA)/glyco-HDCA) specif-
ically, quickly, and significantly activated the NADPH-linked
reductase activity of Akr1b14 and to a lesser extent Akr1b7 activ-
ity (Endo et al., 2011). More accurately, higher specific activation
of Akr1b14 was mediated by an interaction of bile acids with the
His269 facilitating the release of NADP+. In Akr1b7, the histidine
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Table 4 | Expression of aldose reductases in liver and small intestine.
Isoforms Liver Small
intestine
Analyses Tissue-specific transcriptional
regulators
Reference
HUMAN
AKR1B1 + + NB, WB Nrf2 a,b,c
AKR1B10 + + NB, WB, IHC AP1, Nrf2 a,c,d,e,f,g,h
AKR1B15 n.d. n.d. n.d. n.d. –
MOUSE
Akr1b3 + + RT-PCR Nrf2 i,k
Akr1b7 + + RNase protection, RT-qPCR, WB LXR, CAR, PXR, FXR j,l,m,n,o,p,q
Akr1b8 + + RT-PCR, NB Nrf2 i,r,s,t
Akr1b16 + n.d. RT-PCR n.d. s
RAT
Akr1b4 + + RT-PCR, WB n.d. u,v
r-Akr1b10 + − RT-PCR n.d. w
Akr1b13 + + RT-PCR, WB n.d. u,w
Akr1b14 + − RT-PCR n.d. u,w
n.d., not determined; NB, Northern blot; WB, Western blot; RT-PCR, reverse transcription-polymerase chain reaction.
aCao et al. (1998), bO’Connor et al. (1999), cEbert et al. (2011), dFukumoto et al. (2005), eMartin et al. (2006), fHeringlake et al. (2010), gLiu et al. (2012), hNishinaka
et al. (2011), iJoshi et al. (2010), jLau et al. (1995), kNishinaka and Yabe-Nishimura (2005), lVolle et al. (2004), mSchmidt et al. (2011), nGe et al. (2011), oAigueperse et al.
(1999), pLambert-Langlais et al. (2009), qMartinez et al. (2001), rDonohue et al. (1994), sSalabei et al. (2011), tRangasamy et al. (2004), uEndo et al. (2009b), vMacLeod
et al. (2010), wEndo et al. (2010b).
residue found at position 269 in the Akr1b14 protein is replaced
by an arginine residue. This may account for weaker activation
by bile acids. The authors suggested that bile acids could activate
Akr1b14/Akr1b7 when their blood concentrations were elevated.
As high concentrations of hydrophobic bile acids could induce cell
injury through several pathways, e.g., lipid peroxidation, activation
of Akr1b14 by bile acids may increase detoxification of the harmful
lipid peroxidation by-products, and contribute to the attenuation
of toxic effects of bile acids.
Because members of the AKR family (i.e., AKR1C4 and
AKR1D1) were shown to be involved in the bile acid synthe-
sis, Mangelsdorf ’s group hypothesized that FXR-inducible Akr1b7
could be involved in bile acid metabolism in the intestine (Schmidt
et al., 2011). They showed that Akr1b7 overexpression in heterol-
ogous HEK293 cells was associated with a reduction activity of
3-keto bile acids to their 3β-hydroxy derivatives, which are less
toxic than their 3α-hydroxy epimers. Altogether, these results sug-
gest a novel function for Akr1b7 in the detoxification of bile
acids.
Possible role inmetabolic action of bile acids signaling (Figure 5).
In the liver, bile acids are able to influence glucose metabo-
lism by at least two mechanisms. First, conjugated bile acids
rapidly activate the insulin signaling pathway via Gαi protein-
coupled receptors or superoxide ions. In this aspect, they function
much like insulin through the AKT pathway to activate glyco-
gen synthase and repress neoglucogenic genes (Hylemon et al.,
2009). Importantly, bile acids also mediate another control on
liver metabolism through the transcriptional activation of the
gene encoding the small heterodimer partner (SHP) via a func-
tional FXRE in its promoter. The orphan receptor SHP can exert
inhibitory interactions with forkhead box O1 (FOXO1), C/EBPα,
and hepatocyte nuclear factor 4α transcription factors, known
to activate neoglucogenic genes (Yamagata et al., 2004). The
inhibitory control of bile acids on gluconeogenesis has also been
demonstrated in FXR null mice or with the treatment of dia-
betic animals with the FXR agonist GW4064 (Ma et al., 2006;
Zhang et al., 2006). SHP is also able to interact with LXR to
down-regulate the gene encoding SREBP-1c which is the pre-
dominant transactivator for genes encoding enzymes involved
in fatty acid, triglyceride, and VLDL biosynthesis (Horton et al.,
2002).
These observations led Ge et al. (2011) to investigate the impli-
cation of FXR target gene Akr1b7 in liver glucose and lipid metab-
olism using adenovirus-mediated Akr1b7 overexpression. Overex-
pression of hepatic Akr1b7 significantly reduced plasma glucose
levels. This was associated with reduced hepatic mRNA levels of
gluconeogenic genes encoding phosphoenolpyruvate carboxyki-
nase and glucose 6-phosphatase and of peroxisome proliferator-
activated receptor γ co-activator 1α, as well as markedly increased
hepatic SHP mRNA levels. Hepatic lipogenesis was also affected:
mRNA levels of SREBP-1c and several lipogenic genes including
Fas, diacylglycerol acyltransferase 2, cholesterol 7α-hydroxylase,
and the ATP binding cassette G5 were significantly reduced. Nev-
ertheless other FXR target genes such as the bile salt export
protein or the multi drug resistance 2 were not affected. This
excluded the hypothesis that FXR was activated through over-
expression of Akr1b7. Forced hepatic expression of Akr1b7 also
significantly lowered plasma glucose and hepatic triglyceride and
cholesterol levels in db/db mice. These results show that overex-
pression of Akr1b7 in the liver selectively down-regulates gluco-
neogenic and lipogenic gene expression, even though the molec-
ular mechanisms linking Akr1b7 to these metabolic changes are
not elucidated. Yet, we can speculate that up-regulation of the
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FIGURE 5 | Role of Akr1b7 in bile acids metabolism and signaling
pathway. Akr1b7 has the ability to reduce 3-keto bile acids to their less toxic
3β-hydroxy derivatives. In turn, bile acids can stimulate detoxification activity
of Akr1b7, enhancing its capacity to reduce carbonyl and 3-keto bile acids. In
addition to bile acids detoxification, Akr1b7 is also one of their target genes.
In liver and intestine, bile acids induce the FXR-dependent Akr1b7
transcription. The forced expression of Akr1b7 in mouse liver by the mean of
recombinant adenovirus results in the down-regulation of gluconeogenesis
and lipid metabolism. Mechanisms involved are not unravel yet but could rely
on the up-regulation of SHP expression. Increased SHP levels could in turn
repress both FOXO and LXR, leading to the inhibition of gluconeogenic genes
and lipogenic genes, respectively. The mechanism by which Akr1b7
accumulation modulates the SHP gene expression appears independent from
FXR and remains to be discovered (dashed lines).
receptor SHP upon Akr1b7 overexpression has a central role in
the coordinated repression of both gluconeogenic and lipogenic
metabolisms.
Unlike overexpression of Akr1b8/AKR1B10 that leads to
increased lipogenesis, overexpression of Akr1b7 in the liver
reduced hepatic lipid accumulation suggesting that in vivo
these closely related AKR1B proteins display non-overlapping
functions. The possibility that other AR (including AKR1B10)
endowed with 4-HNE reductase activity could modulate bile
acid metabolism under the control of FXR, LXR, or PXR,
remains to be determined. Transcripts for a novel murine ARLP
(Akr1b16) were recently described in the liver but expres-
sion of Akr1b16 has not been investigated in the small intes-
tine (Salabei et al., 2011). Moreover, mechanisms controlling
their expression in these tissues have not yet been eluci-
dated.
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Akr1b3/AKR1B1: altering (liver) metabolic capacity
Both Akr1b3 and AKR1B1 are ubiquitously expressed. Akr1b3
transcripts were detected in the liver and small intestine at similar
levels (Joshi et al., 2010). AKR1B1 messenger RNAs are found in
the liver and small intestine (Cao et al., 1998). Western blot analy-
ses confirmed AKR1B1 expression in the small intestine although
it was undetectable in the normal adult liver. However AKR1B1
expression could be induced by alcoholic cirrhosis (O’Connor
et al., 1999).
In diabetic mice, Akr1b3 is involved in glucose metabolism
in some tissues through its participation in the polyol path-
way. In response to chronic hyperglycemia, Akr1b3 catalyzes the
rate-limiting reduction of glucose into sorbitol which is in turn
converted into fructose by the sorbitol dehydrogenase (SDH).
Activation of this pathway is involved in the development and
progression of diabetic complications (Brownlee, 2001). Some
evidences suggest that it could also be implicated in lipid metab-
olism. First, diabetic patients exhibit elevated blood triglycerides
and non-esterified fatty acids and second, fructose-fed rats display
an elevation of blood triglycerides and a reduction of peroxisome
proliferator-activated receptor alpha (PPARα) activation (Roglans
et al., 2007). These data led Qiu et al. to investigate the effects of
hepatic activation of the Akr1b3/polyol pathway on lipid metab-
olism (Figure 6). In a murine hepatocyte cell line, overexpression
of Akr1b3 was able to suppress PPARα transcriptional activity
through extracellular signal-regulated kinase (ERK1/2)-mediated
inactivating phosphorylations on Ser-12 and Ser-21. This resulted
in decreased expression of genes involved in peroxisomal and
mitochondrial β-oxidation pathway. In addition, Akr1b3 is up-
regulated under high glucose concentrations in mouse hepatocyte
AML12 cells and in vivo in diabetic mice. The genetic ablation or
pharmacological inhibition of Akr1b3 in diabetic mice decreased
ERK1/2-dependent phosphorylation of PPARα and blood triglyc-
erides levels. In diabetic animals, SDH KO was accompanied by
a reduction of blood triglycerides. This study clearly indicated
that Akr1b3 and the polyol pathway sensed intracellular levels
of glucose and adjusted PPARα activity through its phosphory-
lation/dephosphorylation, which in turn affected cellular lipid
homeostasis (Qiu et al., 2008). In db/db mice, inhibition and
knock-down of Akr1b3 induced the decrease of both plasma and
liver triglycerides levels. Inhibition of Akr1b3 in db/db mice led
to an improvement of hepatosteatosis due to the up-regulation
of acetyl-coA oxidase and apolipoprotein A-V, two PPARα target
genes involved in lipid catabolism (Qiu et al., 2012). Mecha-
nisms by which Akr1b3 influences ERK-dependent inactivation
of PPARα remain to be established.
AKR1B1 is also involved in the polyol pathway. Therefore, the
relevance of these results in human remains to be determined.
However, studies using Akr1b3−/− mice or transgenic mice over-
expressing AKR1B1 revealed no abnormalities in either the liver
or small intestine (Yamaoka et al., 1995; Aida et al., 2000).
In addition to this possible implication in metabolism,AKR1B1
could be an actor of small intestine protection against electrophilic
carbonyls. Its expression is also induced in human colon cancer
FIGURE 6 | Role of Akr1b3 in hepatic lipid homeostasis. Diabetic
conditions (high glucose or high fructose) lead to Akr1b3 up-regulation and
Akr1b3-dependent ERK1/2 activation and are often associated to
dyslipidemia. The ERK1/2 mediated phosphorylation of PPARγ inhibits its
transcriptional activity resulting in down-regulation of β-oxidation master
genes. Impaired β-oxidation favors hepatic lipid accumulation and increases
blood triglycerides and non-esterified fatty acids (NEFA). The mechanism by
which Akr1b3 induces ERK1/2 phosphorylation is still unknown (dashed lines).
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cell lines SW-480 and HT-29, by proteasome inhibitors known to
induce Nrf2 expression (Ebert et al., 2011). Characterization of
Akr1b3 promoter has shown that Nrf2 could regulate its activity
through an antioxidant response element 1 (−953 to −945) and
an AP1 site (Nishinaka and Yabe-Nishimura, 2005). The arrange-
ment of these elements in the stress response region was conserved
between Akr1b3 and AKR1B1 promoters (Figure 3).
Moreover, in a similar way as AKR1B10, AKR1B1 displayed
enzymatic properties allowing protection of intestinal cells against
dietary electrophilic carbonyls. Indeed, AKR1B1 kinetic para-
meters are compatible with reduction of glutathione-conjugated
carbonyl compounds (Shen et al., 2011). Studies in healthy tis-
sues could allow a better understanding of AKR1B1 implication
in cytoprotection against oxidative damage.
AKR1B IN WHITE ADIPOSE TISSUE
For decades, adipose tissue was considered an inert mass of energy
storage in which adipocytes were unique in the quantity of lipid
that they can store during period of energy excess and mobi-
lize as free fatty acids when required. In fat pads, adipocytes are
intermingled with other cells including blood cells, endothelial
cells, adipose precursors of varying degree of differentiation, and
fibroblasts (Ailhaud et al., 1992). Adipose tissue plays a crucial
role in the regulation of energy homeostasis, insulin sensitiv-
ity, and lipid/carbohydrate metabolism. These actions are medi-
ated by both non-secreted proteins and hormones produced by
adipocytes. These adipokines have wide-ranging effect on energy
intake, energy expenditure, carbohydrate and lipid metabolism,
including nutrient partitioning, and fuel selection (Trayhurn and
Beattie, 2001; Fonseca-Alaniz et al., 2007; Vázquez-Vela et al.,
2008). White adipose tissue expansion takes place rapidly after
birth and it retains some plasticity throughout life (Frühbeck,
2008). Adipose precursors are able to differentiate in mature
adipocytes and acquire features of fully differentiated cells during
adipogenesis. Acquisition of the adipocyte phenotype is charac-
terized by chronological changes in the expression of numerous
genes. Studies on 3T3-L1 cells, a line of murine preadipocytes
that have the ability to accumulate lipids during their hormonal-
induced differentiation into adipocytes, have allowed identifica-
tion of C/EBPs and PPARγ as master regulators of adipogenesis
(Tontonoz et al., 1994; Wang et al., 1995; Tanaka et al., 1997;
Rosen et al., 1999). The earliest event of adipogenesis is the
transient induction of C/EBPβ and C/EBPδ expression, which in
turn induces PPARγ and C/EBPα expression (Tang et al., 2004).
This is followed by the synergic action of PPARγ and C/EBPα
that enhance the expression of several genes characterizing the
adipocyte phenotype along with massive triglyceride accumula-
tion (Wu et al., 1999). SCD1, phosphoenolpyruvate carboxykinase,
Fas, ACCA, malic enzyme, insulin receptor, adipocyte specific fatty
acid binding protein, leptin (Rosen and Spiegelman, 2000) are
some of the essential genes induced during terminal differentia-
tion of adipocytes. Adipogenesis is tightly regulated by a set of
pro- and anti-adipogenic factors including insulin, FGF, EGF, and
prostaglandins (Gregoire et al., 1998). Adipose tissue expansion is
resulting from adipocyte hyperplasia (generated by an increased
number of adipocytes) and/or hypertrophy (caused by an enlarge-
ment of adipocyte resulting from increased lipid accumulation).
Disruption of the mechanisms that control adipose tissue home-
ostasis can result in massive expansion of the tissue as exemplified
during development of obesity (Henry et al., 2012). One of the
most exciting challenges in the field of adipose tissue homeostasis
is to identify the key regulators of adipose tissue expansion, which
would allow a better understanding of the mechanisms involved
in the pathogenesis of adipose tissue disorders. Recent reports
based on functional studies and identification of novel enzymatic
properties suggest that some AKR1B enzymes can regulate adipose
tissue homeostasis.
Akr1b7: a negative regulator of adipose expansion
Until 2003, there was no mention of AR expression in white adi-
pose tissue. In a transcriptomic study, Moraes et al. reported for
the first time the detection of Akr1b7 mRNA in mouse white
adipose tissue. In this study, the authors highlighted a decrease
in Akr1b7 expression in abdominal white fat tissue from diet-
induced obese mice when compared with mice fed a standard diet
(Moraes et al., 2003). This decrease reflected either the down-
regulation of Akr1b7 gene expression level per cell or the lower
proportion of cells expressing the gene. Indeed, Akr1b7 expres-
sion appeared to vary depending on the location of white adipose
depots and was found enriched in the stromal vascular fraction
(containing adipocyte progenitors) whereas it was virtually absent
from mature adipocytes (Tirard et al., 2007). Accordingly, Akr1b7
expression decreased during adipogenic differentiation of pri-
mary preadipocytes from the stromal vascular fraction and was
detectable in the 3T3-L1 preadipocyte cell line.
The transcription factor SF-1, an essential regulator of Akr1b7
expression in the adrenal cortex is absent from adipose tissue.
Instead, adipocyte precursors express liver receptor homolog-1
(LRH-1; Clyne et al., 2002), a nuclear receptor that also binds
to SF-1 regulatory elements and can substitute for SF-1 in tis-
sues where it is not expressed (Sirianni et al., 2002). Consistent
with decreased expression of Akr1b7 during adipogenesis, LRH-1
expression is rapidly down-regulated during adipocyte differen-
tiation (Clyne et al., 2002). We thus evaluated the possibility
that LRH-1 stimulated Akr1b7 promoter activity in preadipocytes.
Indeed, in co-transfection experiments in 3T3-L1 preadipocytes,
LRH-1 induced Akr1b7 promoter through the SF-1 binding site at
−458 (unpublished observations). Therefore, the dynamic expres-
sion profile of LRH-1 may account for expression of Akr1b7 in the
preadipocytes-enriched stromal fraction (stromal vascular frac-
tion) of various fat depots and its transitory expression in the
early differentiation steps of 3T3-L1 cells.
Overexpression of Akr1b7 in 3T3-L1 preadipocytes prevented
lipid droplets accumulation during adipogenic differentiation. In
contrast, knock-down of Akr1b7 accelerated differentiation and
lipid accumulation in 3T3-L1 cells. These results allowed us to
demonstrate that Akr1b7 is a negative regulator of adipogenesis
in vitro, which prevents differentiation by reducing lipid stor-
age (Tirard et al., 2007). The mechanisms through which Akr1b7
inhibits adipocyte differentiation in vivo were recently unraveled
by our group using Akr1b7−/−mice. These will be discussed below.
Akr1b7 has two different enzymatic activities that could poten-
tially be involved in the regulation of white adipose tissue home-
ostasis. First, just like Akr1b3, Akr1b7 is endowed with PGFS
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activity allowing synthesis of PGF2α, a potent inhibitor of adi-
pogenesis (Serrero et al., 1992; Kabututu et al., 2009). Indeed,
PGF2α is able to inhibit differentiation of 3T3-L1 into adipocytes,
through binding to the FP receptor. Activation of FP recep-
tor in turn blocks PPARγ and C/EBPα expression through a
Gαq-calcium-calcineurin-dependent signaling pathway (Liu and
Clipstone, 2007). PGF2α was also shown to block adipogenesis
through activation of mitogen-activated protein kinase, result-
ing in inhibitory phosphorylation of PPARγ (Reginato et al.,
1998). Second, Akr1b7 reduces 4-HNE, the accumulation of
which is known to induce an excessive development of adi-
pose tissue through adipocytes hypertrophy. Detailed analysis of
Akr1b7−/− mice allowed us to show that Akr1b7 behaved as an
anti-adipogenic factor limiting white adipose tissue expansion,
essentially through the regulation of PGF2α levels in vivo (Volat
et al., 2012; Figure 7).
Akr1b7−/− mice displayed excessive basal adiposity resulting
from both adipocyte hyperplasia and hypertrophy. They further
exhibited increased sensitivity to diet-induced obesity. Following
adipose enlargement and irrespective of the diet, they developed
liver steatosis and progressive insulin-resistance. Akr1b7 loss was
associated with decreased PGF2α white adipose tissue contents.
Cloprostenol (a PGF2α agonist) administration in Akr1b7−/−mice
normalized white adipose tissue expansion by altering both de novo
adipocyte differentiation and size. Treatment of 3T3-L1 adipocytes
and Akr1b7−/− mice with cloprostenol suggested that decreased
adipocyte size resulted from inhibition of lipogenic gene expres-
sion. Hence, Akr1b7 is a major regulator of white adipose tissue
development through at least two PGF2α-dependent mechanisms:
inhibition of adipogenesis and lipogenesis (Volat et al., 2012).
Akr1b8/AKR1B10
Although we showed that Akr1b8 is devoid of PGH2 9-,11-
endoperoxide reductase activity (Kabututu et al., 2009), QTL
mapping allowed identification of Akr1b8 as a possible regula-
tor of adiposity in mouse (Derry et al., 2010). Akr1b8−/− male
mice had a tendency to be fatter than their wild-type littermates,
under both standard and high fat diets. This was particularly obvi-
ous for the gonadal fat pad. Under high fat diet, Akr1b8−/− mice
also displayed higher serum cholesterol than their wild-type lit-
termates. The mechanisms involving Akr1b8 in the regulation
of white adipose tissue homeostasis remain completely unknown
and are not necessarily resulting from expression of the gene in
the adipose tissue. Indeed, we were unable to detect significant
Akr1b8 protein expression in various adipose depots in mouse
(Volat et al., 2012). Although we cannot exclude that Akr1b8 could
be expressed in variable amounts depending on the mouse genetic
background and the location of fat pads, it should be consid-
ered that the effect of Akr1b8 ablation could be indirect. Thus
the involvement of Akr1b8 in adipose tissue homeostasis should
be carefully examined with respect to its expression sites and
enzymatic activities.
AKR1B10 expression in the adipose tissue has not yet been
determined. Because AKR1B10 and Akr1b8 are not only detoxify-
ing enzymes but also affect de novo fatty acids synthesis in cancer
cells, it would be interesting to determine if and which of the
FIGURE 7 | Role of Akr1b7 in adipose tissue homeostasis. In
preadipocytes, arachidonic acid (AA) is metabolized into PGH2 by COX and is
further converted into PGF2α by the PGFS activity of Akr1b7. PGF2α is
supposed to mediate an autocrine activation of FP receptors on
preadipocytes that inhibits their differentiation into adipocytes. In addition,
PGF2α inhibits lipogenesis in mature adipocytes. Accordingly, altered
production of PGF2α in Akr1b7−/− mice leads to an expansion of adipose
tissue due to both hyperplasia and hypertrophy of adipocytes.
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enzymatic activities of AKR1B10 could be involved in adipose tis-
sue homeostasis (Ma et al., 2008; Wang et al., 2009; Joshi et al.,
2010).
Akr1b3/AKR1B1
Akr1b3 is expressed in undifferentiated 3T3-L1 preadipocytes and
during the early phase of their differentiation. Akr1b3 can syn-
thesize PGF2α in 3T3-L1 cells, which inhibits their differentiation
through stimulation of the FP receptor (Fujimori et al., 2010).
In addition to their PGF2α synthase activity, Akr1b3 and
AKR1B1 also catalyze the isomerization of PGH2 to PGD2 (Nagata
et al., 2011). The impact of PGD2 on white adipose tissue home-
ostasis is still very disputed. Indeed, lipocalin-type prostaglandin
D synthase (L-PGDS−/−) mice show hypertrophy of adipocytes
(Ragolia et al., 2005). In contrast, the knock-down of L-PGDS
decreases lipid accumulation in 3T3-L1 cells (Fujimori et al.,
2007). In agreement with these observations, transgenic mice over-
expressing (human hematopoietic-type prostaglandin D synthase
(H-PGDS) overproduce PGD2 and show signs of obesity and pro-
nounced adipogenesis on a high fat diet (Fujitani et al., 2010).
These investigations suggest that PGD2 promotes adipogenesis
in vivo.
Because of its involvement in the synthesis of PGF2α and PGD2,
the involvement of Akr1b3 in white adipose tissue physiology may
result from a balance between both enzymatic activities. However
the relevance of these data has not yet been studied in vivo. Indeed,
no defect in adipose tissue homeostasis have been reported in
Akr1b3−/−mice and the prostaglandin contents of their fat depots
have not been analyzed (Aida et al., 2000; Ho et al., 2000).
Although the murine AR Akr1b3 could potentially participate
in the homeostatic maintenance of adipose tissue, there is no avail-
able information about its human ortholog AKR1B1. Previous
studies using transgenic mice with constitutive overexpression of
AKR1B1 did not report any effect on adipose tissue (Yamaoka et al.,
1995). On the basis of its enzymatic properties (PGF2α and PGD2
synthesis and reduction of 4-HNE), AKR1B1 could be considered
as a potential actor of adipose tissue physiology (Kabututu et al.,
2009; Nagata et al., 2011; Shen et al., 2011). However its expression
pattern in human fat depots remains to be determined.
CONCLUSIVE REMARKS
Understanding physiological functions of AKR1B/Akr1b enzymes
is a really challenging task. In that regard, review of the litera-
ture highlights the marked contrast between the abundance of
enzymatic data and the small number of reports dedicated to func-
tional studies in a physiological context. The main reason for this
discrepancy is likely to be rooted in the functional redundancy
resulting from the obvious structure conservation of the mem-
bers of this enzyme family. Moreover, Akr1b genes being tandemly
arranged on a same chromosome, classical genetic approaches to
study multigene families that consist in combining KO models for
each isoforms to obtain double or triple mutant mice are almost
impossible to setup. Thus, alternative approaches to genetically
disrupt Akr1b in various combinations and locations are manda-
tory to advance our understanding of their functions. Nuclease
targeted invalidation or RNA interference approaches combined
to existing KO models could present as valuable options.
Gain/loss-of-function models available for the Akr1b7 isoform
revealed its implication in metabolic function and adipose tissue
homeostasis. Beside the widely accepted idea that Akr1b are detox-
ification enzymes, several teams have now provided functional
demonstration that some isoforms are endowed with the capacity
to produce directly (prostaglandins) or indirectly (fatty acids) sig-
nal molecules. We think that further exploration of the functions
of AKR1B/Akr1b enzymes must now take this dual potentiality
into account.
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